Country-to-country transfer of patients and the risk of multi-resistant bacterial infectionArchived
This review outlines how increasing modalities of travel, such as aeromedical evacuation of civilians and of military personnel, medical tourism and any shared healthcare across countries, are risks for the transmission of multidrug-resistant organisms via the patient, from country to country.
Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Clinical Infectious Diseases 2011;53(1):49–56
The authors performed a systematic search of the literature looking at inter-country transfer of multiresistant bacterial pathogens like Acinetobacter spp. and Enterobacteriaceae that produce carbapenemases (e.g. Klebsiella pneumoniae carbapenemase (KPC) and the novel New Delhi metallo-β-lactamase (NDM), meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and hypervirulent Clostridium difficile. The authors highlight the increasing potential for travellers and migrants to act as vectors (and victims) of healthcare-associated infections, and outbreaks with these multidrug-resistant bacteria.
In order to prevent the importation and to decrease the spread of these multidrug-resistant bacteria to and within receiving healthcare institutions and countries, the authors propose certain screening recommendations to be implemented. Suggestions are also made regarding how to target therapy based on microbiological results from clinical and screening cultures from these patients.
ECDC comment: This review underscores the risk of transfer of multidrug-resistant bacteria through increasing patient mobility. Caution and vigilance need to be implemented to correctly evaluate the at-risk-patient and to implement infection prevention measures correctly to prevent the importation and spread of these multidrug-resistant bacteria in the healthcare system in the destination country. It is of paramount importance to have a good infection prevention infrastructure to support the necessary infection prevention methods that need to be implemented.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
1 Apr 2019 - ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Conclusions of the twentieth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
11 Mar 2019 - Statement of the twentieth IHR Emergency Committee Regarding the International Spread of Poliovirus, 1 March 2019
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
1 Mar 2019 - On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).